



ICH M11: Clinical electronic Structured Harmonised Protocol (CeSHarP)

Step 2

Step 2 document – to be released for comments

27 September 2022

International Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use

Legal Notice

- This presentation is protected by copyright and may, with the exception of the ICH logo, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the presentation is acknowledged at all times. In case of any adaption, modification or translation of the presentation, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original presentation. Any impression that the adaption, modification or translation of the original presentation is endorsed or sponsored by the ICH must be avoided.
- The presentation is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original presentation be liable for any claim, damages or other liability arising from the use of the presentation.
- The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

Background

- This document has been signed off as a ***Step 2*** document (27 September 2022) to be issued by the ICH Regulatory Members for public consultation
- This document was developed based on a **Concept Paper** (15 November 2018) and a **Business Plan** (15 November 2018)
- Anticipating finalization as a ***Step 4*** document to be implemented in the local regional regulatory system: **October / 2024**

Key Principles – ICH M11 Deliverables

- **ICH M11 is a new harmonised guideline on the clinical protocol that specifies comprehensive organization with standardized content (including both required and optional components).**
- **Deliverables**
 - A Template to include identification of headers, common text and a set of data fields and terminologies which will be the basis for efficiencies in data exchange
 - A Technical Specification that uses an open, nonproprietary standard to enable electronic exchange of clinical protocol information

Key Principles - Template

- **The Template was designed based on general principles that would support a harmonised standard protocol to facilitate consistency and efficiency in the development, amendment, review, conduct and closeout of a clinical trial and the exchange of protocol information.**
- **Principles**
 - Build common core content - The template design represents a core set of information for a clinical trial of any medicinal product(s).

Key Principles - Template

- Serve the needs of stakeholders - The template's structure and content provide a framework for relevant stakeholders to develop, review and use protocols that consistently and unambiguously include a uniform table of contents, common section headers and content, as well as common terminologies.
- Define content for electronic exchange - The protocol content can be electronically exchanged among parties, including sponsors and regulators, using current (for example, electronic common technical document) and other future technologies.

Key Principles - Template

- Design for content re-use - The clinical protocol is a rich source of information that can be re-used as part of the clinical trial management and review process, and, for example, published on clinical trial registries to promote clinical trial transparency and used in standardised clinical trial data capture.
- Maintain flexibility - The template incorporates both recommended and optional text and data fields to maintain flexibility. Higher-level heading structure is conserved, while lower-level sections can be added, removed, or modified as needed.

Key Principles – Technical Specification

- **The Technical Specification includes detailed descriptions of the structured content components (for example, specific data fields and blocks of text-based content), along with other defining attributes and business rules as established in the Template.**

Key Principles – Technical Specification

- **Principles**

- Promote structured common core content
- Define content specifications for electronic exchange
- Develop a data model based on specifications
- Focus on relevant content use and re-use
- Use an open, non-proprietary exchange message standard
- Maintain flexibility for technical innovation and region-specific use

ICH M11 Objectives and Benefits

- **A clinical protocol describes the processes and procedures directing the conduct and analysis of a clinical trial of medicinal product(s) in humans. To date, no internationally adopted harmonised standard has been established for the format and content of the clinical protocol to support consistency across sponsors and for the electronic exchange of protocol information.**

ICH M11 Objectives and Benefits - Guideline

- **The purpose of the Guideline is to describe the general protocol design principles and approach used to develop the separate associated documents, the ICH M11 Clinical electronic Structured Harmonised Protocol Template (Template) and the Technical Specification that are acceptable to all regulatory authorities of the ICH regions.**

ICH M11 Objectives and Benefits - Template

- **The Template presents the format and structure of the protocol, including the table of contents, common headers, and contents.**
- **Use of the clinical trial protocol Template aids the sponsor or sponsor-investigator in the development of a protocol that is complete, free from ambiguity, well organised, and aligned with quality by design principles as set forth in other ICH guidelines.**

ICH M11 Objectives and Benefits - Template

- **By conveying information consistently and in the same location across clinical trial protocols, the protocol Template is intended to provide value to parties that include sponsors, investigators, clinical site personnel, trial participants, ethics committees, and regulators.**

ICH M11 Objectives and Benefits – Technical Specification

- **The Technical Specification presents the conformance, cardinality, and other technical attributes that enable the electronic exchange of protocol content.**
- **The Technical Specification presenting the business requirements and common structured protocol content components and an open, non-proprietary standard for electronic exchange enables development of interoperable electronic tools to facilitate exchange, review, and execution of protocols.**

ICH M11 Scope

- **The Template and Technical Specification are applicable to interventional clinical trials of medicinal products across all phases and therapeutic areas of clinical research.**

ICH M11 Out of Scope

- **Neither the Guideline nor the Template or Technical Specification are intended to specify processes related to development and maintenance of a protocol.**
- **They do not supersede or negate other guidelines that establish requirements for protocol content.**
- **They do not provide instruction on the development of a well-designed trial or characterise a well-crafted final protocol.**

Table of Contents - Guideline

TABLE OF CONTENTS

1.	INTRODUCTION	1
1.1	Background	1
1.2	Purpose	1
1.3	Scope	2
2.	GENERAL DESIGN PRINCIPLES	2
2.1	Clinical Electronic Structured Harmonised Protocol - Template	2
2.2	Clinical Electronic Structured Harmonised Protocol - Technical Specification	3
3.	TEMPLATE CONVENTIONS AND DESIGN.....	4

Table of Contents - Template

114	Table of Contents	
115		
116	1	PROTOCOL SUMMARY 19
117	1.1	Protocol Synopsis 19
118	1.2	Trial Schema 22
119	1.3	Schedule of Activities 22
120	2	INTRODUCTION 23
121	2.1	Purpose of Trial 23
122	2.2	Summary of Benefits and Risks 23
123	3	TRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS 25
124	3.1	{Primary/Secondary/Exploratory} Objective + Associated Endpoint {and Estimand} 25
125	4	TRIAL DESIGN 26
126	4.1	Description of Trial Design 26
127	4.1.1	Participant Input into Design 27
128	4.2	Rationale for Trial Design 27
129	4.2.1	Rationale for Comparator 27
130	4.2.2	Rationale for Adaptive or Novel Trial Design 28
131	4.2.3	Other Trial Design Considerations 28
132	4.3	Access to Trial Intervention After End of Trial 28
133	4.4	Start of Trial and End of Trial 28

Table of Contents - Template

134	5	TRIAL POPULATION.....	29
135	5.1	Selection of Trial Population	29
136	5.2	Rationale for Trial Population.....	29
137	5.3	Inclusion Criteria.....	29
138	5.4	Exclusion Criteria.....	30
139	5.5	Lifestyle Considerations.....	30
140	5.5.1	Meals and Dietary Restrictions.....	30
141	5.5.2	Caffeine, Alcohol, Tobacco, and Other Habits.....	30
142	5.5.3	Physical Activity	30
143	5.5.4	Other Activity	30
144	5.6	Screen Failures	30
145	6	TRIAL INTERVENTION AND CONCOMITANT THERAPY.....	31
146	6.1	Description of Trial Intervention.....	31

Table of Contents - Template

147	6.2	Rationale for Trial Intervention.....	31
148	6.3	Dosing and Administration	32
149	6.3.1	Trial Intervention Dose Modification	32
150	6.4	Treatment of Overdose.....	32
151	6.5	Preparation, Handling, Storage and Accountability.....	32
152	6.5.1	Preparation of Trial Intervention	32
153	6.5.2	Handling and Storage of Trial Intervention	33
154	6.5.3	Accountability of Trial Intervention	33
155	6.6	Participant Assignment, Randomisation and Blinding	33
156	6.6.1	Participant Assignment	33
157	6.6.2	Randomisation	34
158	6.6.3	Blinding and Unblinding.....	34
159	6.7	Trial Intervention Compliance	34
160	6.8	Concomitant Therapy	34
161	6.8.1	Prohibited Concomitant Therapy	35
162	6.8.2	Permitted Concomitant Therapy	35
163	6.8.3	Rescue Therapy.....	35
164	6.8.4	Other Therapy	35

Table of Contents - Template

165	7	DISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT	
166		WITHDRAWAL FROM TRIAL	36
167	7.1	Discontinuation of Trial Intervention.....	36
168	7.1.1	Criteria for Permanent Discontinuation of Trial Intervention	36
169	7.1.2	Temporary Discontinuation or Interruption of Trial Intervention	36
170	7.1.3	Rechallenge.....	36
171	7.2	Participant Withdrawal from the Trial	37
172	7.3	Lost to Follow-Up	37
173	7.4	Trial Stopping Rules.....	37
174	8	TRIAL ASSESSMENTS AND PROCEDURES	38
175	8.1	Screening/Baseline Assessments and Procedures	38
176	8.2	Efficacy Assessments and Procedures	38
177	8.3	Safety Assessments and Procedures.....	38
178	8.3.1	Physical Examination.....	39
179	8.3.2	Vital Signs.....	39

Table of Contents - Template

180	8.3.3	Electrocardiograms	39
181	8.3.4	Clinical Laboratory Assessments.....	39
182	8.3.5	Suicidal Ideation and Behaviour Risk Monitoring	39
183	8.4	Adverse Events and Serious Adverse Events.....	39
184	8.4.1	Definitions of AE and SAE.....	39
185	8.4.2	Time Period and Frequency for Collecting AE and SAE Information.....	40
186	8.4.3	Identifying AEs and SAEs	40
187	8.4.4	Recording of AEs and SAEs.....	40
188	8.4.5	Follow-up of AEs and SAEs.....	40
189	8.4.6	Reporting of SAEs	40
190	8.4.7	Regulatory Reporting Requirements for SAEs.....	40
191	8.4.8	Serious and Unexpected Adverse Reaction Reporting	40
192	8.4.9	Adverse Events of Special Interest	41
193	8.4.10	Disease-related Events or Outcomes Not Qualifying as AEs or SAEs	41
194	8.5	Pregnancy and Postpartum Information.....	41
195	8.5.1	Participants Who Become Pregnant During the Trial.....	41
196	8.5.2	Participants Whose Partners Become Pregnant	42

Table of Contents - Template

197	8.6	Medical Device Product Complaints for Drug/Device Combination Products	42
198	8.6.1	Definition of Medical Device Product Complaints	42
199	8.6.2	Recording of Medical Device Product Complaints	42
200	8.6.3	Time Period and Frequency for Collecting Medical Device Product Complaints .	42
201	8.6.4	Follow-Up of Medical Device Product Complaints	42
202	8.6.5	Regulatory Reporting Requirements for Medical Device Product Complaints.....	42
203	8.7	Pharmacokinetics	43
204	8.8	Genetics.....	43
205	8.9	Biomarkers	43
206	8.10	Immunogenicity Assessments	43
207	8.11	Medical Resource Utilisation and Health Economics.....	44
208	9	STATISTICAL CONSIDERATIONS.....	45
209	9.1	Analysis Sets	45
210	9.2	Analyses Supporting Primary Objective(s).....	45
211	9.2.1	Statistical Model, Hypothesis, and Method of Analysis.....	45

Table of Contents - Template

212	9.2.2	Handling of Intercurrent Events of Primary Estimand(s).....	45
213	9.2.3	Handling of Missing Data.....	46
214	9.2.4	Sensitivity Analysis.....	46
215	9.2.5	Supplementary Analysis.....	46
216	9.3	Analysis Supporting Secondary Objective(s).....	46
217	9.4	Analysis of Exploratory Objective(s).....	46
218	9.5	Safety Analyses.....	46
219	9.6	Other Analyses.....	47
220	9.7	Interim Analyses.....	47
221	9.8	Sample Size Determination.....	47
222	9.9	Protocol Deviations.....	48
223	10	GENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL	
224		OVERSIGHT.....	48
225	10.1	Regulatory and Ethical Considerations.....	48
226	10.2	Committees.....	48
227	10.3	Informed Consent Process.....	48
228	10.4	Data Protection.....	49
229	10.5	Early Site Closure or Trial Termination.....	49

Table of Contents - Template

230	11	GENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY	
231		ASSURANCE.....	50
232	11.1	Quality Tolerance Limits	50
233	11.2	Data Quality Assurance.....	50
234	11.3	Source Data	50
235	12	APPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS –	
236		DEFINITIONS, SEVERITY, AND CAUSALITY	51
237	12.1	Further Details and Clarifications on the AE Definition.....	51
238	12.2	Further Details and Clarifications on the SAE Definition	51
239	12.3	Severity.....	51
240	12.4	Causality.....	51
241	13	APPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS.....	52
242	13.1	Contraception and Pregnancy Testing.....	52
243	13.1.1	Definitions Related to Childbearing Potential	52
244	13.1.2	Contraception.....	52

Table of Contents - Template

245	13.1.3	Pregnancy Testing.....	52
246	13.2	Clinical Laboratory Tests	52
247	13.3	Country/Region-Specific Differences	53
248	13.4	Prior Protocol Amendments	53
249	14	APPENDIX: GLOSSARY OF TERMS	54
250	15	APPENDIX: REFERENCES.....	54

Summary of Guideline Content - Template

- **The Template is designed with the most vital information for execution (for example, Synopsis, Schema, Schedule of Activities) near the front.**
- **Trial-specific information appears earlier in the protocol template, while reference details and more general (non-trial specific) information is in the General Considerations and Appendices. This organisational construct was adopted for its utility during execution. All sections carry equal weight and rigor.**

Summary of Guideline Content – Technical Specification

- **The Technical Specification serves as a technical representation of the Template. This Technical Specification is to be aligned with the latest version of the Guideline and Template, but with flexibility in addressing data exchange needs per ICH and those of regional authorities.**
- **The Technical Specification contains detailed descriptions of information components of the Template.**

Summary of Guideline Content – Technical Specification

- **Example**

12 Overall Rules

Term (Variable)	Overall rules
Data Type	Text
Topic, Value or Header	H
Definition	
User Guidance	
Conformance	Rules
Cardinality	
Relationship content from ToC representing the protocol hierarchy	All document
Relationship (reference to high level conceptual model)	
Value	REQUIRED Level 1 and Level 2 headings
Business rules	Value Allowed: Yes Relationship: n/a Concept: n/a
Duplicate field in other sections	

Considerations

- **The Technical Specification is at an early stage of maturity as certain terms (variables) in this version (e.g., Cardinality, Definition, Relationship to Conceptual Model) are to be addressed post-public consultation as ICH M11 progresses through the formal ICH procedure.**
- **The Template and Technical Specification are versioned documents. As clinical protocol requirements evolve and technology advances, they may be revised subject to a change control process.**

Conclusions

- **A harmonised clinical protocol Template and Technical Specification for electronic exchange of protocol information will enhance the ability of sponsors, regulators, investigators, and other stakeholders to initiate, review, and conduct clinical research, resulting in more efficient drug development and delivery of medicines to patients.**
- **Additional training materials will be developed to complement the Guideline.**

Contact

- **For any questions please contact the ICH Secretariat:**

admin@ich.org